Throughout the year PharmaBoardroom has talked to pharma and biotech executives and life sciences opinion leaders across the globe, gathering vital insights into local markets, learning about promising new therapies,…
A roundup of some of the top news coming out of the Central and Eastern European (CEE) region’s pharma industry, including Poland’s first draft of a national critical medicines list;…
Since raising USD 289 million in its Spring 2020 Hong Kong IPO, InnoCare Pharma has had a remarkable rise. Led by a team of Big Pharma veterans and now also…
US-headquartered global genomic sequencing giant Illumina has endured a tough few years. However, now that various legal wrangles over its acquisition of cancer diagnostics developer GRAIL have been largely resolved…
Eye health, despite being essential for most of us in our daily lives, receives significantly less research funding than fields like cancer or diabetes. According to IQVIA, global spending on…
Diabetes is a growing health concern in China and – given the country’s population size – a major contributor to global diabetes levels. Indeed, a recent study in The Lancet…
There are over 7,000 different rare diseases globally, many of which affect only a handful of patients. However, given the scale of China’s population, rare diseases in the country take…
While China may be grappling with an economic slowdown and escalating geopolitical tensions, it remains the world’s second largest pharma market and a country that boasts an extraordinarily dynamic life…
Beyond political, cultural, economic, and linguistic concerns, the sheer pace of Chinese pharma’s development makes it challenging for international observers to fully grasp the sector’s intricacies, challenges, and numerous opportunities.…
Jazz Pharmaceuticals is about to open a new chapter in its history. As long-standing CEO and co-founder Bruce Cozadd prepares to step down for retirement, the neuroscience and oncology-focused company…
A roundup of top stories from Latin American pharma and healthcare, including the beginning of the Mexican government’s consolidated procurement of medicines; Libbs’ new biologics plant; Novo Nordisk’s USD 142.4…
If the number of strategic deals and industry announcements coming out of the recent CPHI Middle East in Riyadh are anything to go by, Saudi Arabia’s ambition to become a…
See our Cookie Privacy Policy Here
